1997
DOI: 10.1111/j.1365-2222.1997.tb00741.x
|View full text |Cite
|
Sign up to set email alerts
|

Asthma, bronchial hyperreactivity and mediator release in children with birch pollinosis. ECP and EPX levels are not related to bronchial hyperreactivity

Abstract: Signs and symptoms of asthma did not correlate with serum levels of mediators of allergic inflammation. Bronchial hyperreactivity and PEFR variability persisted after the pollen season when signs of bronchial inflammation had disappeared. We hypothesize that eosinophil mediators and other markers of allergic inflammation disappear after the late-phase reaction, whereas BHR persists. This would explain the lack of correlation between the levels of eosinophil mediators in serum and symptoms of asthma and BHR.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2002
2002
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(4 citation statements)
references
References 28 publications
0
4
0
Order By: Relevance
“…17 However, it has previously been suggested that ECP is not related to bronchial hyperreactivity. 18 It is possible that we may have missed the peak effect of ECP release at 15 min, as it has previously been shown that eosinophil degranulation peaks after 10 min incubation with calcium ionophore. 19 Moreover, Takafugi and colleagues demonstrated that neither TNF or GM-CSF could induce ECP release from human eosinophils, 20 and eosinophils from atopic asthmatics did not release ECP after incubation with specific allergen or with anti-IgE monoclonal antibodies.…”
Section: Article In Pressmentioning
confidence: 98%
“…17 However, it has previously been suggested that ECP is not related to bronchial hyperreactivity. 18 It is possible that we may have missed the peak effect of ECP release at 15 min, as it has previously been shown that eosinophil degranulation peaks after 10 min incubation with calcium ionophore. 19 Moreover, Takafugi and colleagues demonstrated that neither TNF or GM-CSF could induce ECP release from human eosinophils, 20 and eosinophils from atopic asthmatics did not release ECP after incubation with specific allergen or with anti-IgE monoclonal antibodies.…”
Section: Article In Pressmentioning
confidence: 98%
“…ECP levels increase during the pollen season or following experimental allergen challenge [39, 40]. However, a number of studies have failed to find a correlation between ECP and other indices of disease activity in asthma such as symptom score, baseline FEV 1 or the degree of bronchial responsiveness [41, 42, 43]. …”
Section: Discussionmentioning
confidence: 99%
“…It has previously been shown that levels of ECP in serum may covariate with disease activity in asthma and serum ECP has been used to monitor clinical asthma [3, 4]. While some have suggested serum ECP to be a useful biomarker to predict response to corticosteroid treatment in asthma [5], the value of this surrogate marker in monitoring asthma has been questioned by others [6]. Theoretically, an optimal marker of disease activity would preferentially reflect physiological responses and activity state of the involved target organ, rather than activity state of circulating primed eosinophils.…”
Section: Introductionmentioning
confidence: 99%